Diabetes
Refine Search
Pharmaceutical
The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) is set to grow at a compound annual growth rate (CAGR) of 13.3% from $2.2 billion in 2023 to $9.9 billion in 2033. 2 January 2025
Generics
Viatris has disclosed that its oral finished-dose manufacturing facility in Indore, India, is subject to regulatory action from the US regulator, after an inspection earlier this year. 24 December 2024
Generics
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter. 24 December 2024
Pharmaceutical
US pharma major Eli Lilly has recently announced a £279 million ($365.5 million) investment in the UK at the International Investment Summit in London. 19 December 2024
Pharmaceutical
The Egyptian Drug Authority has approved EVA Pharma's insulin glargine injection, marking a significant milestone in its collaboration with US pharma major Eli Lilly. 18 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Biotechnology
Novavax has agreed to sell its manufacturing plant in the Czech Republic to Novo Nordisk for $200 million. 6 December 2024
Pharmaceutical
Novo Nordisk will reduce the US list prices of two insulin products, Tresiba (insulin degludec) and Fiasp (insulin aspart), by over 70% from 2026. 6 December 2024
Pharmaceutical
Eli Lilly has announced a $3 billion investment to expand its recently acquired manufacturing facility in Wisconsin, USA. 6 December 2024
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk has announced plans to invest 2.9 billion Danish kroner ($410 million) to establish a cutting-edge quality control laboratory in Hillerød, Denmark. 6 December 2024
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Pharmaceutical
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing Municipal Bureau of Economy and Information Technology and Beijing Economic and Technological Development Zone today to invest approximately 1 billion euros ($1.05 billion) to establish a new manufacturing base. 3 December 2024
Pharmaceutical
Hua Medicine has announced promising new clinical findings for its glucokinase activator dorzagliatin, presented at the China BioMed Innovation and Investment Conference. 2 December 2024
Pharmaceutical
Australia’s Department of Health and Aged Care has developed a new API (application programming interface) for the efficient distribution of the monthly Pharmaceutical Benefits Scheme (PBS) schedule data. 2 December 2024
Biotechnology
Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has announced that AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy program. 18 November 2024
Pharmaceutical
French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland bioproduction site, consolidating its role as a strategic platform dedicated to immunology. 15 November 2024
Pharmaceutical
Privately-held Montanan firm Microbion has announced promising findings from its Phase II study of pravibismane, a topical treatment aimed at addressing diabetic foot ulcer infections (DFI). 14 November 2024
Pharmaceutical
While sky high expectations for Eli Lilly’s tirzepatide have not yet been realized, more positive data add to a growing sense that the future could be as bright as imagined. 14 November 2024
Pharmaceutical
Germany’s Merck KGaA was trading 5% lower as Thursday’s trading day neared its end, after the company announced its third-quarter financial results and outlook for the rest of the year. 14 November 2024
Pharmaceutical
Anglo-Swedish drugmaker AstraZeneca beat analyst expectations with its third-quarter 2024 revenue and earnings figures. 12 November 2024
Pharmaceutical
Pharmaceutical companies that fail to get involved in disease prevention will ‘get left behind’, delegates at an international conference have been told. 16 March 2016
Pharmaceutical
Sanofi and DiCE Molecules, a newly-launched, privately held US company, today announced a five-year global collaboration to create pill versions of therapies to replace injections. 16 March 2016
Pharmaceutical
The Ministry of Health of Ukraine has signed a Memorandum of Understanding (MoU) with a number of manufacturers of insulin aimed for successful implementation of a pilot project to introduce state regulation of prices for insulin and proper provision of medicines to the population of Ukraine. 7 March 2016
Pharmaceutical
Novo Nordisk has announced positive results from a study of its blockbuster drug Victoza (liraglutide). 4 March 2016
Pharmaceutical
Novo Nordisk has presented new data showing that, on average, in the UK, daily administration of Xultophy (insulin degludec/liraglutide; IDegLira), costs less in total and was more effective compared to the separate injections of liraglutide added to basal insulin or compared to basal-bolus regimens. 2 March 2016
Pharmaceutical
US drug regulators have agreed to consider approving a fixed-ratio combination of Lantus (insulin glargine) and Lyxumia (lixisenatide) for the treatment of adults with type 2 diabetes. 23 February 2016
Biosimilars
New Zealand’s Pharmaceutical Management Agency, PHARMAC, this morning announced is interested in considering any proposals from suppliers of the long-acting insulin preparation, insulin glargine (including biosimilar insulin glargine), including associated delivery devices for the treatment of type 1 and type 2 diabetes mellitus. 22 February 2016
Pharmaceutical
The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has finalized a review of SGLT2 inhibitors (a class of type 2 diabetes medicines) and has made recommendations to minimize the risk of diabetic ketoacidosis. 12 February 2016
Pharmaceutical
French pharma major Sanofi posted disappointing financial results for 2015, with fourth-quarter sales down 1.6% at 9.28 billion euros ($10.34 billion) and business net income fell 13.5% lower (at constant exchange rate) to 1.71 billion euros. 9 February 2016
Pharmaceutical
Pharma giant Johnson & Johnson has signed a deal with privately held ViaCyte to co-develop stem cell-based therapies to treat type 1 diabetes. 5 February 2016
Pharmaceutical
Shares in Danish insulin giant Novo Nordisk fell nearly 4.5% in morning trade on the Copenhagen Stock Exchange after the company posted quarterly results below expectations and lowered its long-term profit outlook. 3 February 2016
Pharmaceutical
Danish diabetes care giant Novo Nordisk has released positive headline results from SWITCH 2, the first of two 2x32-weeks randomized, double-blind, cross-over, treat-to-target trials, comparing the safety and efficacy of next-generation diabetes treatment Tresiba (insulin degludec) and insulin glargine. 1 February 2016
Pharmaceutical
German life sciences and pharma company Merck KGaA has officially launched production of its drugs for the treatment of diabetes at the facilities of its Russian partner Nanolek in the Kirov region. 27 January 2016
Pharmaceutical
Investigations of graphene properties for their use as enterosorbents have been performed in SM Kirov Military Medicine Academy in Russia. The research has been carried out under the leadership of Kirsan - Petrik Laboratory of the Future transcorporation. 18 January 2016
Pharmaceutical
US drugmaker MannKind Corp’s shares plunged 48.4% to $0.75 by close of trading on Tuesday, after the company revealed the French pharma major Sanofi has terminated its license and collaboration deal for the development and commercialization of Afrezza (insulin human) Inhalation Powder. 6 January 2016
Pharmaceutical
The global human insulin market is set to touch about $39.13 billion by 2020, growing at compounded annual growth rate of 8.1% from 2015 to 2020, according to a study by research firm MarketsandMarkets. 5 January 2016
Biotechnology
Privately-held US biotech firm Renova Therapeutics says it has obtained an exclusive worldwide license to several patents from the non-profit Research Development Foundation (RDF). 5 January 2016
Biotechnology
Araim Pharmaceuticals has formed a long-term strategic partnership with Vault Bioventures to facilitate the advancement to market of its novel peptide library which targets devastating injuries and chronic diseases underserved by current therapies. 3 January 2016
Pharmaceutical
US drugmaker MannKind Corp today announced the appointment of Duane DeSisto as its president and chief executive, effective January 5, 2016, replacing Alfred Mann who has served as interim CEO since November 19, 2015. 24 December 2015
Biotechnology
Biotech firm Zealand Pharma on Wednesday said it is set to receive a $20 million milestone payment from the French drug major Sanofi following the submission of a New Drug Application for LixiLan to the US Food and Drug Administration. 23 December 2015
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze